| Document |
Document Title |
|
WO/2016/062585A1 |
The present invention relates to a compound of formula (I) wherein: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are as defined herein; and wherein the compound of formula (I) is optionally present as an agrochemically acce...
|
|
WO/2016/052953A1 |
The present specification relates to a (meth)acrylate compound, and a copolymer and a homopolymer comprising a repeating unit derived from the compound.
|
|
WO/2016/052592A1 |
This heat-sensitive recording material is configured to contain, as a color-developing compound, at least one compound represented by one of formulae (1)-(3).
|
|
WO/2016/049774A1 |
Urea-based and bis-urea based compounds and analogues thereof are disclosed. These compounds are useful in the treatment of androgen-dependent diseases or disorders and androgen receptor-mediated diseases or disorders. Specifically, the ...
|
|
WO/2016/049518A1 |
A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)ph
enyl)cyclopentyl)methyl)urea hydrochloride (also referred to "ATR-101") suitable for oral dosing, and to compositions, methods and kits relating ther...
|
|
WO/2016/047356A1 |
The present invention relates to a process for producing a high-purity aqueous urea solution while utilizing a urea production process at least including a urea synthesis step in which urea is synthesized from feed materials to produce a...
|
|
WO/2016/049282A1 |
The invention relates to a compound prepared by (i) reacting (a) at least one compound selected from diisocyanate, polyisocyanate, or mixture thereof; (b) at least one isocyanate-reactive compound selected from a fluorinated alcohol; a c...
|
|
WO/2016/035328A1 |
Provided are: a dispersant which has excellent solubility in a solvent, excellent adhering power to a colorant and excellent colorant dispersibility, while being reduced in self-coloring; a compound and a polymerizable compound for prepa...
|
|
WO/2016/033635A1 |
The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in ...
|
|
WO/2016/030329A1 |
Novel efficient, time-saving and reliable radiofluorination procedures for the production of 18F-labelled active esters via nucleophilic substitution of the corresponding onium precursors with 18F- are described. The active ester includi...
|
|
WO/2016/016178A1 |
The invention relates to the use of a CXCR2 antagonist for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (CIPN).
|
|
WO/2016/013633A1 |
A compound represented by formula (I) or a salt thereof has an excellent noxious organism control activity, particularly an excellent miticidal activity and/or an excellent insecticidal activity, is highly safe, and can be synthesized in...
|
|
WO/2016/010432A1 |
Disclosed is a process for the preparation of a urea product suitable for being diluted with water so as to form an aqueous urea comprising solution for use in a unit for the reduction of NOx in combustion engine exhaust gases, also know...
|
|
WO/2015/188060A1 |
Fluorosulfonyl-substituted sEH inhibitors are compounds represented by Formula (I): wherein R1 is selected from the group consisting of alkyl, heteroalkyi, C5-C12 cycloalkyi, C5-C12 cycloalkylalkyi, C5-C12 cycloalkylheteroalkyi, arylalky...
|
|
WO/2015/181186A1 |
The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions con...
|
|
WO/2015/176135A1 |
The present invention relates to new omega-3 fatty acid analogues and to their use in cancer therapy, including anti-metastatic therapy.
|
|
WO/2015/165352A1 |
The present invention provides a compound with a structure represented by general formula I or a pharmaceutically acceptable salt thereof, a preparation method for the compound or the salt, and a use of the compound or the pharmaceutical...
|
|
WO/2015/158792A1 |
The invention relates to rheology control agents comprising at least one active substance of general formula (I) and at least one active substance of general formula RB4OOC-NH-RB3-NH-CO-NRB2-(CH2)x-RB1-(CH2)x-RB2-CO-NH-RB3-NH-
COORB4, to...
|
|
WO/2015/158794A1 |
The invention relates to a urea preparation containing (A) 5 to 75 wt.% of one or more urea components which have a molecular weight of at least 350 g/mol and contain at least one urea group; (B) 15 to 95 wt.%, preferably 30 to 80 wt.%, ...
|
|
WO/2015/136292A1 |
The invention relates to a DDX3X inhibitorfor use in the treatment of pneumovirus infection in a mammal, wherein the DDX3X inhibitor may be a compound of Formula (I) wherein y, Z, R1, X, L, Ra and Rb are as defined herein. The invention ...
|
|
WO/2015/134839A1 |
Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula (I): or pharmaceutically acceptable...
|
|
WO/2015/126150A1 |
The present application relates to a t-butyl ketone binaphthol derivative and a method for manufacturing same, the t-butyl ketone binaphthol derivative being a high-efficiency chiral-extracting agent which has very high chiral selectivit...
|
|
WO/2015/109666A1 |
Disclosed are an ester group-containing aromatic propionamide compound, and a preparation method therefor and uses thereof, and provides a chemical structure formula of the new ester group-containing aromatic propionamide compound. The c...
|
|
WO/2015/019192A3 |
There are provided pyrrolysine analogues of the formulae (X), (I), (II), (V), (VI), (VII) and (VIII), in which the a, b, d, X, Y, Z, FG, R, R1, R2 and R3 are as defined in the claims, which are useful in bioconjugation processes and muta...
|
|
WO/2015/100252A1 |
Felbamate deuterated at the 2 position, compositions containing the same, and methods of making and using thereof are described herein. Substitution of the hydrogen at the 2 position with deuterium should prevent or reduce formation of t...
|
|
WO/2015/092807A1 |
The present invention provides a novel process for preparing Alogliptin free base and its benzoate salt which comprises insitu condensation process to produce protected Alogliptin by reacting 6-chloro-3-methylpyrimidine-2, 4(1H, 3H)-dion...
|
|
WO/2015/089962A1 |
Provided is a method for continuously preparing biuret polyisocyanate, comprising: a mixed solution of a diisocyanate and a catalyst with water vapour, in an aerosol form, are continuously reacted in a first reactor; the product obtained...
|
|
WO/2015/089271A1 |
A compound, or a protonate or salt thereof, having a formula I of: wherein Y represents an optionally substituted aromatic group; n is 1 or 2; a is 0 to 4; R1 and R2 are each independently H; optionally substituted alkyl; optionally subs...
|
|
WO/2015/084299A1 |
Disclosed herein are gemini surfactants, and methods for making and using these gemini surfactants. These gemini surfactants may be incorporated in paints and coatings to provide hydrophilic and/or self-cleaning properties. Coatings and ...
|
|
WO/2015/080665A1 |
The invention relates to compounds of formula (I) or derivatives, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites or prodrugs thereof, in which ...
|
|
WO/2015/056164A1 |
The invention relates to a process for the synthesis of Cariprazine, an antipsychotic compound useful in the treatment of positive and negative symptoms associated to schizophrenia, with the following structural formula: (A) The inventio...
|
|
WO/2015/056782A1 |
The purpose of the present invention is to provide a novel compound having ACC2-inhibiting activity and to provide a pharmaceutical composition comprising said compound. A compound indicated by formula (in the formula, R1 indicates a sub...
|
|
WO/2015/039172A1 |
The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.
|
|
WO/2015/040425A1 |
A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: Y is –CONR1- or optionally substituted arylene or optionally substituted heteroarylene; R1 is H, Cl, F, CH3 or CF3; 10 each R4 is independently H, CH3 or ...
|
|
WO/2015/042071A1 |
The present invention relates to diphenyl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor 2.
|
|
WO/2015/030085A1 |
A photosensitive layer comprises: a phthalocyanine crystal in which a urea compound is contained. The urea compound has one or more urea moieties comprising: a carbonyl group, or a thiocarbonyl group, and two nitrogen atoms. Each of the ...
|
|
WO/2015/012407A1 |
The present invention pertains to a cellulose acylate film containing a compound having at least one linking group selected from the group consisting of a bivalent linking group represented by -NH-(C=O)-O- and a bivalent linking group re...
|
|
WO/2015/009545A1 |
The present invention relates to derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide 2 receptor.
|
|
WO/2015/002918A1 |
There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, suc...
|
|
WO/2014/184248A3 |
Compounds of Formula (I), pharmaceutically acceptable salts thereof, diastereomers, enantiomers, or mixtures thereof: wherein R1, R2, R3, X, Yn and A are as defined in the specification, as well as pharmaceutical compositions including t...
|
|
WO/2014/207960A1 |
Provided are a method for effectively removing triuret from aqueous urea, a method for producing high purity aqueous urea, and a method for recovering triuret from aqueous urea. To this end, the method for producing aqueous urea comprise...
|
|
WO/2014/202703A1 |
The present invention relates to novel strobilurine type compounds I, processes for preparing these compounds, a use of compounds of the formula I and/or their agriculturally useful salts for controlling phytopathogenic fungi, to composi...
|
|
WO/2014/176636A9 |
The invention provides compounds of Formula (I), and methods of treating or preventing a bacterial infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufactur...
|
|
WO/2014/192823A1 |
Provided is a urea synthesis method of excellent reliability and productivity, the method minimizing the amount of oxygen used as an anti-corrosion agent without using a special two-phase stainless steel. In the urea synthesis device, wh...
|
|
WO/2014/183221A1 |
Resveratrol analogs and their use to inhibit Kv1.5 channels are provided. The resveratrol analogs are useful in the treatment of atrial arrhythmias, including atrial fibrillation (AF). Exemplary resveratrol analogs are compounds of gener...
|
|
WO/2014/184116A1 |
The invention relates to new carbodiimides having terminal urea and/or urethane groups of formula (I), wherein R can be the same or different and is selected from the group of the -NHCONHR', -NHCONR'R'', and -NHCOOR''' residues. The inve...
|
|
WO/2014/184248A2 |
Compounds of Formula (I), pharmaceutically acceptable salts thereof, diastereomers, enantiomers, or mixtures thereof: wherein R1, R2, R3, X, Yn and A are as defined in the specification, as well as pharmaceutical compositions including t...
|
|
WO/2014/176636A1 |
The invention provides compounds of Formula (I), and methods of treating or preventing a bacterial infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufactur...
|
|
WO/2014/174745A1 |
Compared to a traditional Eg5 (KSP: kinesin spindle protein) inhibitor, this water-soluble polycyclic compound or a pharmacologically acceptable salt thereof has a greater solubility in an aqueous solvent and has Eg5 inhibitory activity ...
|
|
WO/2014/158654A1 |
Compounds of formula (II): wherein A, R1, R2, R5 and R13 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well...
|
